Ranibizumab: in diabetic macular oedema (Q34166795)

31 July 2017

title

Ranibizumab: in diabetic macular oedema (English)

1 reference

31 July 2017

James E Frampton

1

1 reference

31 July 2017

publication date

1 March 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

72

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

509-523

1 reference

https://scigraph.springernature.com/pub.10.2165/11208410-000000000-00000

31 July 2017

exact match

0 references

cites work

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Current approaches to the management of diabetic retinopathy and diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Burden of illness of diabetic macular edema: literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Macular edema. A complication of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Optimal current and future treatments for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208410-000000000-00000

Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab

21 January 2018

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

10.2165/11208410-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1040527286

0 references

1 reference